The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerUrinary biomarkers for prostate cancerRisk calculators and updated tools to select and plan a repeat biopsy for prostate cancer detectionProstate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal BiomarkersSerum markers in prostate cancer detectionEvaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies.Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers.An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.Novel biomarkers for the detection of prostate cancer.Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.Addressing the need for repeat prostate biopsy: new technology and approaches.Developing a model for forecasting Gleason score ≥7 in potential prostate cancer patients to reduce unnecessary prostate biopsies.Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study.Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.Next-generation prostate cancer risk calculator for primary care physicians.The molecular biology of prostate cancer: current understanding and clinical implications.Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome.Urinary markers aiding in the detection and risk stratification of prostate cancer
P2860
Q26738703-A92AB912-F7C4-4704-B6A7-D414E9E5BAD0Q27009110-61858379-72C7-4D82-988D-1EE127146982Q27027085-BBAD14DD-5355-48E5-ACEB-3C8FB5DF4EEAQ28075610-AAE7E939-0506-48CA-B246-FA42155676AFQ35042519-269C6945-C00D-4DA1-A81D-CDD9D73DBF0BQ36336025-4CBCB5F1-D0CD-4A01-8FB3-443421B4478CQ37273884-0522E17B-CA34-4D40-B838-95707144BC90Q37691113-9EBD45D7-9405-4664-BCA7-898F271627A0Q37708174-97DFD72A-4AA0-4F02-850D-062E5DD43A89Q38546301-BF550B8E-A0C9-4B29-85FC-BA325930F2DAQ38546671-4947C8AA-15B9-4B77-A876-D337E6B21998Q38916152-03486ABF-F20B-48F5-BA9A-D0E06D960C22Q39003646-4D254526-2F38-4BD3-B523-AF8E780E2299Q39331903-386B2CB8-EA2C-4729-9ACD-FA24F3CA02B1Q47704685-EC3C6A91-3D6A-4BEC-B979-EDC388FFFE8DQ49546811-5FA52E2A-DFD6-462B-B6B9-E3A6D0B1160BQ54996710-BF7A9552-8370-4669-833B-F481494BFD29Q58562073-981AF988-1253-4EBC-8000-A8EAFF6BF98D
P2860
The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The added value of percentage ...... ate cancer in prescreened men.
@ast
The added value of percentage ...... ate cancer in prescreened men.
@en
type
label
The added value of percentage ...... ate cancer in prescreened men.
@ast
The added value of percentage ...... ate cancer in prescreened men.
@en
prefLabel
The added value of percentage ...... ate cancer in prescreened men.
@ast
The added value of percentage ...... ate cancer in prescreened men.
@en
P2093
P2860
P1433
P1476
The added value of percentage ...... tate cancer in prescreened men
@en
P2093
Esther W de Bekker-Grob
Ewout W Steyerberg
Geert J L H van Leenders
Hans G Lilja
Moniek M Vedder
P2860
P304
P356
10.1016/J.EURURO.2014.08.011
P407
P577
2014-08-26T00:00:00Z